174例肺癌患者抗肿瘤药物应用评价分析_李艳.pdfVIP

中南药学2020 年8 月第 18 卷 第 8 期　Central South Pharmacy. August, Vol.18 No.8 174 例肺癌患者抗肿瘤药物应用评价分析 1 2* 1 1 1 1 （1. 咸阳市中心医院药学部，陕西　咸阳　712000；2. 西安交通大学 李艳 ，封卫毅 ，仝敏，吴琳，岳明，姚欢 第一附属医院药学部，西安　710061） 摘要：目的　分析某院肺癌患者抗肿瘤药物应用现状及合理性，为临床合理用药提供参考。方法　收集 2019 年某院收治的 174 例原发性肺癌患者资料，统计患者抗肿瘤治疗方案、辅助性药物、肿瘤药物相 关不良反应等情况，依据药品说明书和临床实践指南对抗肿瘤药物使用的合理性进行评价，按照不良事 件评价标准（CTCAE5.0 ）分析安全性。结果　肿瘤药物与肿瘤辅助性药物均存在不合理现象，不合理 现象覆盖用药指征、药物品种遴选、用法用量、药物配伍禁忌、超说明书用药等诸多方面。结论　肿瘤 治疗药物和辅助性用药的不合理现象较为突出，医疗机构应重视抗肿瘤药物本身及相关辅助性药物的合 理性评价工作，进一步促进临床规范合理用药。 关键词：肺癌；抗肿瘤药物；合理性评价；安全用药 中图分类号：R969.3　　　　文献标识码：A　　　　文章编号：1672-2981(2020)08-1405-05 doi:10.7539/j.issn.1672-2981.2020.08.025 Rational use of antineoplastic drugs in 174 lung cancer patients 1 2* 1 1 1 1 LI Yan , FENG Wei-yi , TONG Min , WU Lin , YUE Ming , YAO Huan ( 1. Department of Pharmacy, Xianyang Central Hospital, Xianyang Shaanxi 712000; 2. Department of Pharmacy, the First Affiliated ’ ’ Hospital of Xi an Jiaotong University, Xi an 710061) Abstract: Objective To determine the status quo and rationality of antineoplastic drug use in lung cancer patients in a hospital. Methods Date of 174 lung cancer inpatients in 2019 were collected. Antineoplastic chemotherapy regimens, adjuvant drugs and adverse drug reactions, etc. were analysed retrospectively. We evaluated the rationality of the application of antineoplastic drugs according to the instructions and clinical practice guidelines of lung cancer, as well as standard treatment schemes. Safety was evaluated according to the CTACE 5.0 criteria for adverse events. Results Both antineoplastic drugs and antineoplastic auxiliary drugs showed irrational usage in aspects such